Physician profile
Emily E Ewing
NPI 1386388858
$4,068.58
in general payments reported to CMS, 2019-2025
42 companies · $2,406 in 2025
The $2,406 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $447 · 2023: $588 · 2024: $628 · 2025: $2,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,621.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $409.97 | 2025 | |
| Novo Nordisk INC | $276.19 | 2023-2025 | Ozempic, Rybelsus |
| Amgen INC. | $211.17 | 2024 | Krystexxa |
| Neurelis, INC. | $202.60 | 2024-2025 | Valtoco |
| Sk Life Science, INC. | $172.48 | 2025 | |
| Lilly USA, LLC | $149.55 | 2022-2025 | Kisunla |
| Edwards Lifesciences Corporation | $142.90 | 2022 | |
| Inspire Medical Systems, INC. | $140.68 | 2023 | Inspire |
| Axsome Therapeutics, INC. | $137.07 | 2025 | Symbravo |
| Biogen, INC. | $134.14 | 2025 | Vumerity |
| Alkermes, INC. | $129.38 | 2025 | Lybalvi |
| Ucb, INC. | $129.19 | 2025 | Briviact, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $128.69 | 2025 | Austedo Xr |
| Tg Therapeutics, INC. | $124.02 | 2025 | |
| Nevro Corp. | $122.25 | 2023 | Senza |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $118.00 | 2024-2025 | Vyepti |
| Idorsia Pharmaceuticals US INC | $111.78 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $107.98 | 2025 | |
| Boston Scientific Corporation | $101.41 | 2022 | |
| Hologic Sales and Service, LLC | $93.20 | 2024 | Aptima |
| Xeris Pharmaceuticals, INC. | $92.82 | 2023 | Gvoke Hypopen |
| Myovant Sciences INC. | $82.46 | 2022 | |
| Genentech USA, INC. | $79.77 | 2024-2025 | Ocrevus Zunovo |
| Pfizer INC. | $69.50 | 2024 | |
| Merz Pharmaceuticals, LLC | $64.83 | 2025 | Xeomin, Ampyra, Inbrija |
| Ani Pharmaceuticals, INC. | $61.52 | 2024-2025 | Purified Cortrophin Gel |
| Csl Behring | $56.37 | 2024-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $48.57 | 2025 | |
| Amneal Pharmaceuticals LLC | $47.78 | 2025 | Crexont |
| Grifols USA, LLC | $45.03 | 2025 | Gamunex-C |
| Tanabe Pharma America, INC. | $32.40 | 2025 | Radicava |
| Vanda Pharmaceuticals INC. | $29.37 | 2024-2025 | Ponvory |
| Emd Serono, INC. | $27.98 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $26.76 | 2025 | Dysport |
| Argenx US, INC. | $25.27 | 2025 | Vyvgart Hytrulo |
| Ge Healthcare | $24.75 | 2025 | |
| Janssen Biotech, INC. | $23.89 | 2025 | |
| Merck Sharp & Dohme LLC | $23.75 | 2023 | M-M-R II, Vaxneuvance, Gardasil 9 |
| Biotronik Nro, INC. | $21.15 | 2025 | Prospera |
| Octapharma USA, INC. | $19.05 | 2024 | Panzyga |
| Astrazeneca Pharmaceuticals LP | $16.15 | 2025 | Wainua |
| Organon LLC | $6.76 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Ewing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.